Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

Overview

Journal Arthritis Rheumatol

Publisher Wiley

Specialty Rheumatology

Date 2023 Jul 25

PMID 37488962

Authors

Ji Soo Kim

Adrianne Woods

Laura Gutierrez-Alamillo

Maureen Laffoon

Fredrick M Wigley

Laura K Hummers

Antony Rosen

Scott Zeger

Robyn T Domsic

Livia Casciola-Rosen

Ami A Shah

Affiliations

Soon will be listed here.

Abstract

Objectives: We examined whether an array of scleroderma autoantibodies associates with risk of cancer and could be useful tools for risk stratification.

Methods: Scleroderma cancer cases and scleroderma controls without cancer from the Johns Hopkins Scleroderma Center and the University of Pittsburgh Scleroderma Center were studied. Sera were assayed by Lineblot and enzyme-linked immunosorbent assay (ELISA) for autoantibodies against centromere, topoisomerase 1, RNA polymerase (POLR) 3, PM/Scl, Th/To, NOR90, U3 RNP, Ku, Ro52, U1RNP, and RNPC3. Logistic regression models were constructed to examine whether distinct autoantibodies associated with overall cancer at any time and cancer-associated scleroderma (cancer occurring three years before and after scleroderma onset). The effects of having more than one autoantibody on cancer were further examined using random forest analysis.

Results: A total of 676 cases and 687 controls were studied. After adjusting for relevant covariates, anti-POLR3 (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.03-2.11) and monospecific anti-Ro52 (OR 2.19, 95% CI 1.29-3.74) were associated with an increased overall cancer risk, whereas anticentromere (OR 0.69, 95% CI 0.51-0.93) and anti-U1RNP (OR 0.63, 95% CI 0.43-0.93) were associated with lower risk. When examining risk of cancer-associated scleroderma, these immune responses remained associated with increased or decreased risk: anti-POLR3 (OR 2.28, 95% CI 1.33-3.91), monospecific anti-Ro52 (OR 2.58, 95% CI 1.05-6.30), anticentromere (OR 0.39, 95% CI 0.20-0.74), and anti-U1RNP (OR 0.32, 95% CI 0.11-0.93). Anti-Ro52 plus anti-U1RNP or anti-Th/To was associated with decreased cancer risk compared with anti-Ro52 alone.

Conclusions: These data suggest that five distinct scleroderma immune responses, alone or in combination, may be useful tools to stratify the risk of cancer for scleroderma patients. Further study examining cancer risk in autoantibody subgroups relative to the general population is warranted.

Citing Articles

Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.

Tonutti A, Motta F, Isailovic N, Ceribelli A, Ragusa R, Nappi E RMD Open. 2024; 10(3.

PMID: 39306344 PMC: 11418480. DOI: 10.1136/rmdopen-2024-004492.

SOX-5 Transcription Factor: a Novel Psoriatic Autoantigen Preferentially Found in Women.

Orbai A, Fiorentino D, Perin J, Darrah E, Yang Q, Gutierrez-Alamillo L ACR Open Rheumatol. 2024; 6(12):807-819.

PMID: 39218617 PMC: 11638130. DOI: 10.1002/acr2.11740.

References

Joseph C, Darrah E, Shah A, Skora A, Casciola-Rosen L, Wigley F . Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2013; 343(6167):152-7. PMC: 4038033. DOI: 10.1126/science.1246886. View

Gauderon A, Roux-Lombard P, Spoerl D . Antinuclear Antibodies With a Homogeneous and Speckled Immunofluorescence Pattern Are Associated With Lack of Cancer While Those With a Nucleolar Pattern With the Presence of Cancer. Front Med (Lausanne). 2020; 7:165. PMC: 7204906. DOI: 10.3389/fmed.2020.00165. View

Lazzaroni M, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R . Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. J Rheumatol. 2017; 44(5):639-647. DOI: 10.3899/jrheum.160817. View

Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F . Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol. 2011; 38(7):1329-34. DOI: 10.3899/jrheum.101144. View

Shah A, Igusa T, Goldman D, Li J, Casciola-Rosen L, Rosen A . Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. Arthritis Res Ther. 2021; 23(1):64. PMC: 7905617. DOI: 10.1186/s13075-021-02449-3. View

Hosono Y, Sie B, Pinal-Fernandez I, Pak K, Mecoli C, Casal-Dominguez M . Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies. Ann Rheum Dis. 2022; 82(2):246-252. PMC: 9870850. DOI: 10.1136/ard-2022-222441. View

Koga T, Okamoto M, Satoh M, Fujimoto K, Zaizen Y, Chikasue T . Positive Autoantibody Is Associated with Malignancies in Patients with Idiopathic Interstitial Pneumonias. Biomedicines. 2022; 10(10). PMC: 9598916. DOI: 10.3390/biomedicines10102469. View

Koszewicz M, Michalak S, Bilinska M, Budrewicz S, Zaborowski M, Slotwinski K . Is peripheral paraneoplastic neurological syndrome possible in primary brain tumors?. Brain Behav. 2016; 6(6):e00465. PMC: 4851647. DOI: 10.1002/brb3.465. View

Brauner S, Zhou W, Backlin C, Green T, Folkersen L, Ivanchenko M . Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. J Intern Med. 2015; 278(3):323-32. DOI: 10.1111/joim.12375. View

10.

Shah A, Rosen A, Hummers L, Wigley F, Casciola-Rosen L . Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010; 62(9):2787-95. PMC: 2946521. DOI: 10.1002/art.27549. View

11.

Atalay C, Dogan L, Atalay G . Anti-CENP-B antibodies are associated with prolonged survival in breast cancer. Future Oncol. 2010; 6(3):471-7. DOI: 10.2217/fon.10.6. View

12.

Ding Q, He D, He K, Zhang Q, Tang M, Dai J . Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers. Tumour Biol. 2015; 36(11):8761-72. DOI: 10.1007/s13277-015-3572-2. View

13.

Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W . Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther. 2011; 13(6):R211. PMC: 3334664. DOI: 10.1186/ar3544. View

14.

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

15.

Bernal-Bello D, Garcia de Tena J, Guillen-Del Castillo A, Selva-OCallaghan A, Callejas-Moraga E, Marin-Sanchez A . Novel risk factors related to cancer in scleroderma. Autoimmun Rev. 2017; 16(5):461-468. DOI: 10.1016/j.autrev.2017.03.012. View

16.

Saigusa R, Asano Y, Nakamura K, Miura S, Ichimura Y, Takahashi T . Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. J Dermatol. 2015; 42(5):524-7. DOI: 10.1111/1346-8138.12827. View

17.

Mecoli C, Adler B, Yang Q, Hummers L, Rosen A, Casciola-Rosen L . Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. Arthritis Rheumatol. 2020; 73(2):315-323. PMC: 7884482. DOI: 10.1002/art.41493. View

18.

Marie I, Hatron P, Dominique S, Cherin P, Mouthon L, Menard J . Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2011; 41(6):890-9. DOI: 10.1016/j.semarthrit.2011.09.008. View

19.

Shah A, Xu G, Rosen A, Hummers L, Wigley F, Elledge S . Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma. Arthritis Rheumatol. 2017; 69(6):1306-1312. PMC: 5449218. DOI: 10.1002/art.40065. View

20.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View